| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 08/01/2002 | WO2002059325A2 Human kinases and polynucleotides encoding the same |
| 08/01/2002 | WO2002059324A2 Novel inositol polyphosphate kinase genes and uses thereof |
| 08/01/2002 | WO2002059323A2 Aminoacyl trna synthetases |
| 08/01/2002 | WO2002059322A2 Compositions and methods relating to the daptomycin biosynthetic gene cluster |
| 08/01/2002 | WO2002059321A2 Hepatitis c virus replicons and replicon enhanced cells |
| 08/01/2002 | WO2002059320A2 Dna sequences of escherichia coli cft073 |
| 08/01/2002 | WO2002059319A1 Malaria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen |
| 08/01/2002 | WO2002059318A1 A humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof |
| 08/01/2002 | WO2002059317A2 Cub domain protein zcub3 and materials and methods for making it |
| 08/01/2002 | WO2002059316A2 Human ion exchanger proteins and polynucleotides encoding the same |
| 08/01/2002 | WO2002059315A2 Human nucleic acids and polypeptides and methods of use thereof |
| 08/01/2002 | WO2002059314A2 A human melanoma associated antigen and uses therefor |
| 08/01/2002 | WO2002059313A2 G-protein coupled receptors and nucleic acids encoding same |
| 08/01/2002 | WO2002059312A2 Cell adhesion proteins |
| 08/01/2002 | WO2002059311A2 Colon cancer marker |
| 08/01/2002 | WO2002059310A2 Polynucleotides encoding cellular transporters and methods of use thereof |
| 08/01/2002 | WO2002059309A2 Anthozoa derived chromoproteins, fluorescent mutants thereof and methods for using the same |
| 08/01/2002 | WO2002059308A2 Method of diagnosing and treating cartilage disorders |
| 08/01/2002 | WO2002059307A2 Human ltrpc7 proteins, nucleic acid molecules encoding them, and uses thereof |
| 08/01/2002 | WO2002059306A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 08/01/2002 | WO2002059305A1 Method of detecting ethiologic factor of bronchial asthma |
| 08/01/2002 | WO2002059304A1 Novel g protein-coupled receptor protein and dna thereof |
| 08/01/2002 | WO2002059303A1 Nurr1 transcription factor i-box mutants having monomeric transcriptional activation activity |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059301A1 Chemokines |
| 08/01/2002 | WO2002059300A2 Double-stranded rna-mediated gene suppression |
| 08/01/2002 | WO2002059299A2 Expression cloning method |
| 08/01/2002 | WO2002059298A2 Gab2(p97) gene and methods of use thereof |
| 08/01/2002 | WO2002059297A2 A library of a collection of cells |
| 08/01/2002 | WO2002059296A2 Concatemers of differentially expressed multiple genes |
| 08/01/2002 | WO2002059295A1 Novel serine protease mp493 |
| 08/01/2002 | WO2002059294A1 Methods and means for producing efficient silencing construct using recombinational cloning |
| 08/01/2002 | WO2002059293A2 Process and compositions for peptide, protein and peptidomimetic synthesis |
| 08/01/2002 | WO2002059292A2 Functional balanced-lethal host-vector systems |
| 08/01/2002 | WO2002059291A2 Biological organism for preparing pharmaceutical compositions for treating mammals |
| 08/01/2002 | WO2002059290A2 A method for evolving a cell having desired phenotype and envolved cells |
| 08/01/2002 | WO2002059287A2 Novel human kinases and polynucleotides encoding the same |
| 08/01/2002 | WO2002059286A2 Adenylate cyclases |
| 08/01/2002 | WO2002059284A2 33217, a human amp-binding enzyme family member and uses thereof |
| 08/01/2002 | WO2002059283A2 Nucleic acid modification enzymes |
| 08/01/2002 | WO2002059282A2 Adipocyte complement related protein zacrp13 |
| 08/01/2002 | WO2002059281A2 High level cytokine production with enhanced cell viability |
| 08/01/2002 | WO2002059278A2 Differentiation of stem cells to pancreatic endocrine cells |
| 08/01/2002 | WO2002059272A2 Covalent chemical inducers of protein dimerization and their uses in high throughput binding screens |
| 08/01/2002 | WO2002059270A2 Methods and compositions for expressing polynucleotides specifically in smooth muscle cells in vivo |
| 08/01/2002 | WO2002059269A2 Maintenance of genic male-sterile female parental lines using a maintainer line with a stable engineered chromosome |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059266A2 Dna encoding human alpha and beta subunits of neuronal nicotinic acetylcholine receptor |
| 08/01/2002 | WO2002059264A2 Specific human antibodies for selective cancer therapy |
| 08/01/2002 | WO2002059263A2 Transgenic animals comprising a humanized immune system |
| 08/01/2002 | WO2002059262A2 Compositions and methods for detecting proteolytic activity |
| 08/01/2002 | WO2002059259A2 Methods for discovering secreted and transmembrane proteins |
| 08/01/2002 | WO2002059257A2 Method and means for producing barley yellow dwarf virus resistant cereal plants |
| 08/01/2002 | WO2002059256A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | WO2002059155A2 Modulation of calcium channel activity |
| 08/01/2002 | WO2002059154A2 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 08/01/2002 | WO2002059153A2 Anticoagulants and their uses |
| 08/01/2002 | WO2002059151A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 08/01/2002 | WO2002059150A2 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 08/01/2002 | WO2002059149A2 Pro-apoptotic proteins and dna molecules encoding them |
| 08/01/2002 | WO2002059148A2 A method for identification, isolation and production of antigens to a specific pathogen |
| 08/01/2002 | WO2002059147A2 Activatable cytolytic or drug delivery peptides and uses thereof |
| 08/01/2002 | WO2002059140A2 Ikaros rgulatory elements and uses thereof |
| 08/01/2002 | WO2002059138A1 A method for regulating genes with electromagnetic response elements |
| 08/01/2002 | WO2002059136A2 Immunoglobulin class switch recombination |
| 08/01/2002 | WO2002059093A1 Methods and compositions for binding nucleic acid molecules |
| 08/01/2002 | WO2002058885A1 Pressure vessel systems and methods for dispensing liquid chemical compositions |
| 08/01/2002 | WO2002058728A2 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 08/01/2002 | WO2002058727A2 Recombinant plasmodium falciparum merozoite protein-1/42 vaccine |
| 08/01/2002 | WO2002058724A2 Use of lp82 to treat body weight disorders |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058546A2 Methods for screening for substances which inhibit fp prostanoid receptor |
| 08/01/2002 | WO2002058533A2 Process for determining target function and identifying drug leads |
| 08/01/2002 | WO2002058532A2 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof |
| 08/01/2002 | WO2002058459A2 Transgenic trees having increased resistance to imidazolinone herbicides |
| 08/01/2002 | WO2002058450A2 Regulation of cell growth by muc1 |
| 08/01/2002 | WO2002043864A3 Devices and methods for biochip multiplexing |
| 08/01/2002 | WO2002042480A3 Modified vaccinia ankara virus variant |
| 08/01/2002 | WO2002036832A3 Atropisomers of asymmetric xanthene fluorescent dyes and methods of dna sequencing and fragment analysis |
| 08/01/2002 | WO2002036761A9 Compositions and methods for the diagnosis of cancer |
| 08/01/2002 | WO2002036740A9 Apoptosis-inducing ribozymes |
| 08/01/2002 | WO2002033107A3 Plant cell death system |
| 08/01/2002 | WO2002033106A3 Plant cell death system |
| 08/01/2002 | WO2002033105A3 Reducing oxidative stress of plants by increasing glutathione content |
| 08/01/2002 | WO2002032923A3 Improved formulations using heat shock/stress protein-peptide complexes |
| 08/01/2002 | WO2002031157A3 Shrimp alkaline phosphatase |
| 08/01/2002 | WO2002028876A3 Oligonucleotide linkers comprising a variable cohesive portion and method for the preparation of polynucleotide libraries by using said linkers. |
| 08/01/2002 | WO2002022804A3 Compositions and methods for stable transformation using mu bacteriophage cleaved donor complex |
| 08/01/2002 | WO2002022681A3 Neuronally expressed protein and use thereof |
| 08/01/2002 | WO2002020614A3 Endoglin-specific polypeptide, production and use thereof |
| 08/01/2002 | WO2002016620A3 Modulation of stem cell differentiation |
| 08/01/2002 | WO2002016617A3 Myrosinase from brevicoryne brassicae |
| 08/01/2002 | WO2002016437A3 Rhabdovirus-based vectors to express high levels of functional human antibodies |
| 08/01/2002 | WO2002014495A3 Enhanced homologous recombination mediated by lambda recombination proteins |
| 08/01/2002 | WO2002010745A3 Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage |
| 08/01/2002 | WO2002010365A3 Down-regulation of single genes and simultaneous down-regulation of multiple genes by nuclear localization of rna transcripts |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002004509A3 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |